Whiz Partners

What Whiz Partners does

Whiz Partners Inc. is an independent Japanese investment management firm founded in September 2010 when it spun off from CSK Venture Capital under the leadership of Toshio Ando, former Chairman of the Japan Securities Dealers Association. The firm operates two distinct investment strategies from its Tokyo headquarters (Atago Green Hills MORI Tower, Minato-ku). First, it executes PIPEs (Private Investment in Public Equities) for small and mid-cap listed Japanese companies, combining convertible bonds and warrants with VC-style hands-on support to catalyze business development, partnerships, and M&A. Second, it invests in unlisted companies through full-hands-on private equity, including corporate carve-outs, joint venture formation, and platform company building. The firm is a registered Financial Instruments Business Operator (Kanto Local Finance Bureau Director-General (Kinsho) No. 2590) with permits for investment management, advisory, and Type II financial instruments business.

The firm's core product set comprises eight investment funds (seven raised since 2010, plus PIGAF currently being raised) with cumulative capital managed of approximately JPY 80 billion (~USD 530M). Fund vintages span Healthcare PE Fund I (JPY 5.32B, 2011), Whiz Asia Evolution (JPY 12.54B, 2013), Whiz Healthcare Japan 2.0 (JPY 15.48B, 2014), THE KENKO FUTURE (JPY 6.0B, 2017), Whiz AIoT Evolution (JPY 5.7B, 2018), Drug Discovery Renaissance (JPY 18.0B, 2018), Healthcare New Platform (JPY 10.85B, 2021), and PIGAF (2025). Revenue is generated through three streams: recurring fund management fees calculated on committed or invested AUM, success-based carried interest tied to fund hurdle rates, and advisory fees for portfolio company business development support.

Whiz's most significant value creation has come through platform companies that it designed and built from inception. Axcelead, Japan's first integrated drug discovery orchestration hub, was carved out from Takeda Pharmaceutical in 2019 and now serves 300+ global pharma clients across 200+ active projects with a 1.2M+ compound library. ARCALIS, established in 2021 as a joint venture between Axcelead and US-based Arcturus Therapeutics, operates GMP-compliant commercial mRNA manufacturing facilities in Minamisoma (Fukushima) and Kashiwa (Chiba), producing Meiji Seika Pharma's Kostaive COVID-19 vaccine and serving as a strategic node in Japan's biopharmaceutical economic security infrastructure. The firm is governed by President & CEO Tomoyuki Fujisawa (appointed November 2024), CFO Junichi Kajimoto, COO Tatsuya Yamada, and CIO Yuki Hasegawa, with special advisors Hiroshi Okuda and Hideto Ozaki (former Toyota leadership) supporting since founding.

Name

Whiz Partners

Legal name

Whiz Partners Inc.

Website

https://whizp.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Whiz Partners is an independent Japanese private equity and PIPEs fund manager focused on healthcare, biotech, AI, and digital transformation, managing approximately JPY 80 billion across eight funds and serving institutional LPs, listed SMEs, and unlisted ventures through its platform companies Axcelead and ARCALIS.

Ownership category

akta.pro rank

Product category

Private Equity Investment Management

NAICS

All Other Financial Investment Activities (52399), Miscellaneous Intermediation (523910)

SIC

Investment Advice (6282), Services-Management Consulting Services (8742)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Private equity funds
• PIPEs investment
• Healthcare investment
• Investment management
• Biotech venture capital

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Fund Management Fees: Management fees calculated as a percentage of committed or invested capital under management, charged annually to fund investors (LPs) over the fund lifecycle.
2. Carried Interest (Performance Fees): Success-based performance fees tied to investment returns exceeding specified hurdle rates. Aligned incentive structure linking fund manager returns to investor outcomes.
3. Investment Advisory Services: Consulting and advisory services for portfolio companies on business development, partnerships, and M&A support.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels4 records

Core offering

Whiz Partners is an independent investment firm managing private equity and PIPEs (Private Investments in Public Equities) funds focused on healthcare, biotech, AI/IoT, and digital transformation sectors. The firm provides hands-on operational support alongside capital through convertible bonds and warrants for listed companies and full engagement in private company creation, including carve-outs and joint ventures. Platform companies Axcelead (drug discovery) and ARCALIS (mRNA CDMO) operate within the firm's ecosystem.

Product overview

Whiz Partners is an independent investment firm offering two primary investment approaches: (1) PIPEs (Private Investment in Public Equities) combining convertible bonds and warrants with hands-on operational support for listed companies, and (2) Private Equity investing from company creation through active management participation. The firm manages multiple specialized funds across healthcare, AI/IoT, and technology sectors. Its platform companies include Axcelead, a drug discovery orchestration hub integrating AI and wet research capabilities, and ARCALIS, an mRNA therapeutics CDMO operating GMP-compliant manufacturing facilities. The firm positions itself as an industry designer rather than a passive capital allocator.

Differentiator

Problem solved

Functional benefit

Products and services

• PIPEs Investment Services
• Private Equity Investment Services
• Axcelead Drug Discovery Platform
• ARCALIS mRNA CDMO
• Whiz Healthcare PE Fund I
• Whiz Asia Evolution Fund
• Whiz Healthcare Japan 2.0 Fund
• THE KENKO FUTURE Fund
• Whiz AIoT Evolution Fund
• Drug Discovery Renaissance Fund
• Healthcare New Platform Fund
• Post-IPO Growth Acceleration Fund (PIGAF)

Quantifiable outcome

• JPY 80 billion cumulative capital managed across 7+ funds
• +3 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Ten partnerships are on record, tiered strategic, core and minor.

• All Nippon Asset Management Co., Ltd. (オールニッポン・アセットマネジメント)strategicGTM or Marketing Partner · 1 June 2026Partnership with regional financial institution networks to provide sophisticated alternative investment services. Combines All Nippon Asset Management's regional financial institution relationships with Whiz Partners' private equity and alternative investment expertise to meet diverse and sophisticated asset management needs.
• Nissan Chemical Corporation (日产化学)coreTechnology or Integration · 1 February 2026License agreement for DNA-Encoded Library (DEL) technology. Axcelead gains access to Nissan Chemical's accumulated compound assets and DEL screening capabilities to expand its drug discovery orchestration services and compound library for pharmaceutical clients.
• RealizeEdge PartnersstrategicStrategic or Co-development Partner · 1 November 2025Drug Antibody Conjugate (DAC) / Degrader Antibody Conjugate candidate generation research contract. Axcelead applies its drug discovery platform capabilities (target identification, lead optimization, preclinical evaluation) to create promising DAC candidates in collaboration with RealizeEdge.
• Meiji Seika Pharma (明治 Seika ファルマ)coreChannel Partner/ Reseller/ Distributor · 1 February 2025ARCALIS certified as domestic manufacturing site for Meiji Seika Pharma's mRNA COVID-19 vaccine 'Kostaive' (コスタイベ筋注用). ARCALIS provides domestic GMP-compliant manufacturing; Meiji Seika distributes in Japan. Critical for Japan's vaccine self-sufficiency and economic security.
• IPGaia / Tohoku UniversityminorStrategic or Co-development Partner · 10 June 2024IPGaia, a Whiz Partners portfolio company, entered a master collaborative research and development agreement with Tohoku University for joint R&D activities in healthcare/biotech.
• Teijin (帝人)strategicStrategic or Co-development Partner · 3 July 2023Joint venture for drug discovery research between Teijin and Axcelead. Combines Teijin's pharmaceutical research capabilities with Axcelead's integrated drug discovery platform services for early-stage drug development collaboration.
• Arcturus Therapeutics (United States)coreStrategic or Co-development Partner · 27 April 2021Japan-US joint venture for mRNA therapeutics manufacturing. Arcturus provides self-amplifying mRNA (sa-mRNA) technology platform; Whiz Partners/Axcelead provides Japanese market access and operational infrastructure. ARCALIS established as Asia-Pacific's first GMP-compliant commercial mRNA manufacturing facility.
• Hitachi (日立製作所)strategicStrategic or Co-development Partner · 7 April 2021Co-development agreement with Axcelead for solutions contributing to early creation of next-generation biopharmaceuticals. Joint development combining Hitachi's technology capabilities with Axcelead's drug discovery platform.
• Takeda Pharmaceutical IndustrycoreStrategic or Co-development Partner · 1 January 2019Takeda carved out its drug discovery platform to create Axcelead. Whiz Partners led the carve-out from Takeda, with Axcelead inheriting Takeda's research capabilities and becoming fully independent in 2019. This established the foundation for Whiz Partners' drug discovery platform strategy.
• Shanghai Oriental Pearl Media / CRI MiddlewareminorStrategic or Co-development Partner · 12 November 2015Strategic alliance for game development middleware market expansion into China. CRI Middleware partnered with Shanghai Media Group for distribution; Whiz Partners (via Asia Evolution Fund) invested JPY 880M to support overseas expansion and M&A.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Nihon M&A Center: Japan's largest M&A intermediary supporting SMEs and mid-market companies. Comparable in providing M&A advisory and capital introduction services to Japanese mid-cap companies, though Whiz Partners adds direct investment alongside advisory support.
• Carlyle Japan: Global private equity firm with substantial Japan operations and dedicated healthcare and technology funds. Comparable as a competing capital source for Japanese healthcare and biotech companies, though at much larger scale and broader sector mandate.

Direct peers

• JAFCO Group: Japan's largest venture capital and private equity firm, with substantial healthcare/biotech investment focus and a track record of fund-of-funds and direct PE investing. Comparable as a Japan-domiciled growth equity investor targeting similar mid-cap healthcare and technology companies.
• Unison Capital: Japan-focused middle-market private equity firm known for operational engagement and carve-out transactions. Comparable in its hands-on approach to portfolio companies and Japan mid-market healthcare/services focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments24 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Whiz Partners